República de Sud-àfrica - anglès - South African Health Products Regulatory Authority (SAHPRA)

viatris healthcare (pty) ltd - tablet - see ingredients - each tablet contains atorvastatin calcium equivalent to 20,0 mg atorvastatin

República de Sud-àfrica - anglès - South African Health Products Regulatory Authority (SAHPRA)

viatris healthcare (pty) ltd - tablet - see ingredients - each tablet contains atorvastatin calcium equivalent to 40,0 mg atorvastatin

República de Sud-àfrica - anglès - South African Health Products Regulatory Authority (SAHPRA)

viatris healthcare (pty) ltd - tablet - see ingredients - each tablet contains atorvastatin 80,0 mg

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - atorvastatin calcium trihydrate, quantity: 10.85 mg (equivalent: atorvastatin, qty mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; hyprolose; polysorbate 80; magnesium stearate; calcium carbonate; microcrystalline cellulose; lactose monohydrate; titanium dioxide; macrogol 8000; hypromellose; purified talc; purified water; methyl hydroxybenzoate; dimeticone 1000; sorbitan monostearate; polysorbate 60; guar gum; bronopol - lipitor is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. lipitor is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - atorvastatin calcium trihydrate, quantity: 86.8 mg (equivalent: atorvastatin, qty 80 mg) - tablet, film coated - excipient ingredients: magnesium stearate; polysorbate 80; croscarmellose sodium; hyprolose; lactose monohydrate; calcium carbonate; microcrystalline cellulose; purified water; methyl hydroxybenzoate; dimeticone 1000; sorbitan monostearate; polysorbate 60; guar gum; bronopol; titanium dioxide; macrogol 8000; hypromellose; purified talc - lipitor is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. lipitor is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - atorvastatin calcium trihydrate, quantity: 43.4 mg (equivalent: atorvastatin, qty 40 mg) - tablet, film coated - excipient ingredients: polysorbate 80; magnesium stearate; calcium carbonate; croscarmellose sodium; lactose monohydrate; microcrystalline cellulose; hyprolose; purified water; methyl hydroxybenzoate; dimeticone 1000; sorbitan monostearate; polysorbate 60; guar gum; bronopol; titanium dioxide; macrogol 8000; hypromellose; purified talc - lipitor is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. lipitor is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - atorvastatin calcium trihydrate, quantity: 21.7 mg (equivalent: atorvastatin, qty 20 mg) - tablet, film coated - excipient ingredients: hyprolose; calcium carbonate; croscarmellose sodium; microcrystalline cellulose; magnesium stearate; polysorbate 80; lactose monohydrate; titanium dioxide; macrogol 8000; hypromellose; purified talc; purified water; methyl hydroxybenzoate; dimeticone 1000; sorbitan monostearate; polysorbate 60; guar gum; bronopol - lipitor is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. lipitor is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - atorvastatin calcium -

Malta - anglès - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - atorvastatin - film-coated tablet - atorvastatin 20 mg - lipid modifying agents

Malta - anglès - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - atorvastatin - film-coated tablet - atorvastatin 40 mg - lipid modifying agents